Status:
RECRUITING
Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance
Lead Sponsor:
Auburn University
Conditions:
Mood Disturbance
Eligibility:
All Genders
18-50 years
Phase:
EARLY_PHASE1
Brief Summary
The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main ...
Detailed Description
Clinical assessments will include phlebotomy (completed at weeks 0 and 8) and questionnaires which will be completed at weeks 0, 4, and 8 to assess changes in mood disorder symptomology and serum BDNF...
Eligibility Criteria
Inclusion
- Adults age 18-50
- Depression subscale score of \>9/21 on the DASS-21
- No change in medications or supplements over the past 3 months
- Can read and speak English
Exclusion
- Currently consume curcumin or green tea daily
- Currently, pregnant, nursing, or trying to become pregnant
- Currently diagnosed with a perimenopausal disorder
Key Trial Info
Start Date :
September 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06531863
Start Date
September 30 2024
End Date
August 1 2025
Last Update
February 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Auburn University School of Kinesiology
Auburn, Alabama, United States, 36849